GILD - Gilead Sciences.
Financial Amalysis: The company had 1.32 Bil, 2.03 Bil and 3.03 Bil in revenues for 2004 - 2006. Current estimates for the year are extremely low (3.95 to 4 Bil). The company has exceeded revenues quarter over quarter every time. current estimates are for no Quarter over Quarter growth. They have beaten estimates conprehensively and for a 40% growth rate, their Future P/E is only 23 (given current low estimates). The technicals for the stock are great and they are hovering around 50 day EMA. Look for the stock to climb over 81.5 for a continued run and over 84.47 for a real unabated run. If stock rises into earnings then sell options prior to earnings (high premium) and sell stock after earnings. Option activity today is definitely favorable and in anticipation of a positive earnings surprise.
The stock has an excellent pipeline of drugs and just recently got approved for ambrisentan for treatment of pulmonary arterial hypertension, to be marketed as Letairis. This one feels like it's going to a 100.
Cheers,
Ahu
No comments:
Post a Comment